Qiagen has received CE-IVD marks for its assays to identify and quantify Epstein-Barr virus and human herpes virus 6.

The assays are intended to monitor the viral load of immunocompromised patients, including organ transplant patients.

The assays use automated three-step solutions that extract DNA from blood or urine to isolate the target nucleic acids for analysis using real-time polymerase chain reaction (RT-PCR) equipment, delivering results in about one hour.

The company says it also plans to launch a monkeypox assay later this year for research and surveillance of the two known forms of circulating monkeypox virus, Clade I and Clade II.

Qiagen now has 16 assays that have received the CE-IVD mark.